Loading
A phase 3 trial of Pembrolizumab, Atezolizumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by InSightec, now recruiting.
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets is a phase 3 interventional study registered as NCT05317858 by InSightec, with 30 participants planned, started 2022-08-12 and due to reach its primary completion in 2027-06-01. Interventions recorded: Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab. Conditions listed: Brain Tumor, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cemiplimab, Atezolizumab, Nivolumab, Small-cell lung cancer.
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Atezolizumab, Nivolumab, Small-cell lung cancer, Pembrolizumab.
Shares Cemiplimab, Atezolizumab, Nivolumab, Pembrolizumab.
Shares Atezolizumab, Nivolumab, Small-cell lung cancer, Pembrolizumab.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/